{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:52:49Z","timestamp":1793134369647,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T00:00:00Z","timestamp":1389225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T00:00:00Z","timestamp":1389225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/leu.2014.3","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T02:41:39Z","timestamp":1389235299000},"page":"1472-1477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":481,"title":["CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons"],"prefix":"10.1038","volume":"28","author":[{"given":"A","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T L","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Knudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C H","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Caramazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"BFleu20143_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ceca.2013.05.006","volume":"54","author":"P Eggleton","year":"2013","unstructured":"Eggleton P, Michalak M . Calreticulin for better or for worse, in sickness and in health, until death do us part. Cell Calcium 2013; 54: 126\u2013131.","journal-title":"Cell Calcium"},{"key":"BFleu20143_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1172\/JCI12412","volume":"107","author":"K Nakamura","year":"2001","unstructured":"Nakamura K, Robertson M, Liu G, Dickie P, Guo JQ, Duff HJ et al. Complete heart block and sudden death in mice overexpressing calreticulin. J Clin Invest 2001; 107: 1245\u20131253.","journal-title":"J Clin Invest"},{"key":"BFleu20143_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1083\/jcb.144.5.857","volume":"144","author":"N Mesaeli","year":"1999","unstructured":"Mesaeli N, Nakamura K, Zvaritch E, Dickie P, Dziak E, Krause KH et al. Calreticulin is essential for cardiac development. J Cell Biol 1999; 144: 857\u2013868.","journal-title":"J Cell Biol"},{"key":"BFleu20143_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.it.2012.08.002","volume":"34","author":"M Raghavan","year":"2013","unstructured":"Raghavan M, Wijeyesakere SJ, Peters LR, Del Cid N . Calreticulin in the immune system: ins and outs. Trends Immunol 2013; 34: 13\u201321.","journal-title":"Trends Immunol"},{"key":"BFleu20143_CR5","doi-asserted-by":"publisher","first-page":"e56387","DOI":"10.1371\/journal.pone.0056387","volume":"8","author":"D Lee","year":"2013","unstructured":"Lee D, Oka T, Hunter B, Robinson A, Papp S, Nakamura K et al. Calreticulin induces dilated cardiomyopathy. PLoS One 2013; 8: e56387.","journal-title":"PLoS One"},{"key":"BFleu20143_CR6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.biocel.2012.02.009","volume":"44","author":"WA Wang","year":"2012","unstructured":"Wang WA, Groenendyk J, Michalak M . Calreticulin signaling in health and disease. Int J Biochem Cell Biol 2012; 44: 842\u2013846.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFleu20143_CR7","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1038\/cddis.2010.82","volume":"1","author":"M Wemeau","year":"2010","unstructured":"Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 2010; 1: e104.","journal-title":"Cell Death Dis"},{"key":"BFleu20143_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1096\/fj.09-145482","volume":"24","author":"LI Gold","year":"2010","unstructured":"Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010; 24: 665\u2013683.","journal-title":"FASEB J"},{"key":"BFleu20143_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/stem.85","volume":"27","author":"S Papp","year":"2009","unstructured":"Papp S, Dziak E, Opas M . Embryonic stem cell-derived cardiomyogenesis: a novel role for calreticulin as a regulator. Stem Cells 2009; 27: 1507\u20131515.","journal-title":"Stem Cells"},{"key":"BFleu20143_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/emboj.2009.1","volume":"28","author":"T Panaretakis","year":"2009","unstructured":"Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578\u2013590.","journal-title":"EMBO J"},{"key":"BFleu20143_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/BJ20081847","volume":"417","author":"M Michalak","year":"2009","unstructured":"Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M . Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009; 417: 651\u2013666.","journal-title":"Biochem J"},{"key":"BFleu20143_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54\u201361.","journal-title":"Nat Med"},{"key":"BFleu20143_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/386843a0","volume":"386","author":"MG Coppolino","year":"1997","unstructured":"Coppolino MG, Woodside MJ, Demaurex N, Grinstein S, St-Arnaud R, Dedhar S . Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 1997; 386: 843\u2013847.","journal-title":"Nature"},{"key":"BFleu20143_CR14","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.humpath.2013.07.009","volume":"44","author":"O Vaksman","year":"2013","unstructured":"Vaksman O, Davidson B, Trope C, Reich R . Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Human Pathol 2013; 44: 2677\u20132683.","journal-title":"Human Pathol"},{"issue":"7","key":"BFleu20143_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/jcp.24519","volume":"229","author":"Weiwei Sheng","year":"2014","unstructured":"Sheng W, Chen C, Dong M, Zhou J, Liu Q, Dong Q et al. Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. J Cell Physiol 2013; e-pub ahead of print 22 November 2013; doi:10.1002\/jcp.24519.","journal-title":"Journal of Cellular Physiology"},{"key":"BFleu20143_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000335267","volume":"82","author":"A Eric-Nikolic","year":"2012","unstructured":"Eric-Nikolic A, Milovanovic Z, Sanchez D, Pekarikova A, Dzodic R, Matic IZ et al. Overexpression of calreticulin in malignant and benign breast tumors: relationship with humoral immunity. Oncology 2012; 82: 48\u201355.","journal-title":"Oncology"},{"key":"BFleu20143_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ajmg.b.30300","volume":"141B","author":"A Aghajani","year":"2006","unstructured":"Aghajani A, Rahimi A, Fadai F, Ebrahimi A, Najmabadi H, Ohadi M . A point mutation at the calreticulin gene core promoter conserved sequence in a case of schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 294\u2013295.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFleu20143_CR18","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J Med 2013; 369: 2391\u20132405.","journal-title":"New Engl J Med"},{"key":"BFleu20143_CR19","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med 2013; 369: 2379\u20132390.","journal-title":"New Engl J Med"},{"key":"BFleu20143_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937\u2013951.","journal-title":"Blood"},{"key":"BFleu20143_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011; 25: 82\u201388.","journal-title":"Leukemia"},{"key":"BFleu20143_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392\u2013397.","journal-title":"J Clin Oncol"},{"key":"BFleu20143_CR23","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27: 1504\u20131510.","journal-title":"Leukemia"},{"key":"BFleu20143_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ajh.23373","volume":"88","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013; 88: 201\u2013206.","journal-title":"Am J Hematol"},{"issue":"2","key":"BFleu20143_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2013.286","volume":"28","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Finke CM, Lasho TL, Wassie EA, Knudson R, Ketterling RP et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 2013; e-pub ahead of print 7 October 2013; doi:10.1038\/leu.2013.286.","journal-title":"Leukemia"},{"key":"BFleu20143_CR26","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","volume":"120","author":"TL Lasho","year":"2012","unstructured":"Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012; 120: 4168\u20134171.","journal-title":"Blood"},{"key":"BFleu20143_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/leu.2011.253","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012; 26: 475\u2013480.","journal-title":"Leukemia"},{"key":"BFleu20143_CR28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/leu.2011.320","volume":"26","author":"TL Lasho","year":"2012","unstructured":"Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 2012; 26: 1135\u20131137.","journal-title":"Leukemia"},{"key":"BFleu20143_CR29","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861\u20131869.","journal-title":"Leukemia"},{"key":"BFleu20143_CR30","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","volume":"118","author":"P Guglielmelli","year":"2011","unstructured":"Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011; 118: 5227\u20135234.","journal-title":"Blood"},{"key":"BFleu20143_CR31","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","volume":"117","author":"R Vaidya","year":"2011","unstructured":"Vaidya R, Caramazza D, Begna KH, Gangat N, Van Dyke DL, Hanson CA et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood 2011; 117: 5612\u20135615.","journal-title":"Blood"},{"key":"BFleu20143_CR32","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/leu.2011.374","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia 2012; 26: 1439\u20131441.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu20143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20143","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:27:06Z","timestamp":1648729626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu20143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,9]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["BFleu20143"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,9]]},"assertion":[{"value":"30 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}